Financial Contrast: Biomerica (NASDAQ:BMRA) and Integer (NYSE:ITGR)

Integer (NYSE:ITGR) and Biomerica (NASDAQ:BMRA) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, dividends and earnings.

Analyst Recommendations

This is a breakdown of recent recommendations for Integer and Biomerica, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Integer	0	13	1	0	2.07
Biomerica	1	0	0	0	1.00

Integer currently has a consensus price target of $109.86, suggesting a potential downside of 13.10%. Biomerica has a consensus price target of $9.00, suggesting a potential upside of 284.62%. Given Biomerica’s higher possible upside, analysts clearly believe Biomerica is more favorable than Integer.

Earnings & Valuation

This table compares Integer and Biomerica”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Integer	$1.85 billion	2.32	$102.81 million	$3.66	34.54
Biomerica	$4.45 million	1.62	-$3.78 million	($1.27)	-1.84

Integer has higher revenue and earnings than Biomerica. Biomerica is trading at a lower price-to-earnings ratio than Integer, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Integer has a beta of 0.62, indicating that its share price is 38% less volatile than the S&P 500. Comparatively, Biomerica has a beta of 0.37, indicating that its share price is 63% less volatile than the S&P 500.

Institutional & Insider Ownership

99.3% of Integer shares are owned by institutional investors. Comparatively, 22.3% of Biomerica shares are owned by institutional investors. 1.1% of Integer shares are owned by insiders. Comparatively, 18.0% of Biomerica shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Integer and Biomerica’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Integer	6.97%	12.79%	6.48%
Biomerica	-84.79%	-97.19%	-61.57%

Summary

Integer beats Biomerica on 12 of the 14 factors compared between the two stocks.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures. It also provides cardiac rhythm management products, including implantable pacemakers, implantable cardioverter defibrillators, insertable cardiac monitors, implantable cardiac pacing and defibrillation leads, and heart failure therapies; neuromodulation products, such as implantable spinal cord stimulators; and non-rechargeable batteries, feedthroughs, device enclosures, machined components, and lead components and sub-assemblies. In addition, the company offers rechargeable batteries and chargers; and arthroscopic, laparoscopic, and general surgery devices and components, such as harmonic scalpels, shaver blades, burr shavers, radio frequency probes, biopsy probes, trocars, electrocautery components, wound dressings, GERD treatment components, and phacoemulsification needles. Further, it provides orthopedic products that include instruments used in hip, knee, and spine surgeries, as well as reamers and chisels. Additionally, the company offers customized battery power and power management systems, and battery solutions for the energy, military, and environmental markets. Furthermore, the company provides medical technologies. It serves multi-national original equipment manufacturers and their affiliated subsidiaries in the cardiac rhythm management, neuromodulation, orthopedics, vascular, and advanced surgical and portable medical markets. Integer Holdings Corporation was founded in 1970 and is headquartered in Plano, Texas.

About Biomerica

Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications; or to measure bacteria, hormones, antibodies, antigens, or other substances which may exist in the human body, stools, or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods IBS, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; and H. Pylori diagnostic test that indicates if a patient is infected with the H. Pylori bacteria. In addition, it develops products to indicate if a person has been infected by COVID-19. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.